Price$17.44-1.47 (-7.77%)
2026-02-132026-05-19
News · 26 weeks24-75%
2025-12-142026-06-07
Mix1990d
- Other11(58%)
- SEC Filings3(16%)
- Insider2(11%)
- Earnings1(5%)
- Leadership1(5%)
- Offering1(5%)
Latest news
25 items- SECSEC Form F-6 POS filed by PureTech Health plcF-6 POS - PureTech Health plc (0001782999) (Subject)
- SECSEC Form 424B3 filed by PureTech Health plc424B3 - PureTech Health plc (0001782999) (Filer)
- SECSEC Form 15F-12B filed by PureTech Health plc15F-12B - PureTech Health plc (0001782999) (Filer)
- PRPureTech to Showcase Deupirfenidone Program at the American Thoracic Society International ConferencePresentations to highlight differentiated approach to advancing deupirfenidone, reinforcing its potential to serve as a new standard of care within the evolving idiopathic pulmonary fibrosis treatment landscape PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced presentations showcasing its deupirfenidone (LYT-100) program at the upcoming American Thoracic Society (ATS) International Conference, taking place in Orlando, Florida, from May 15-20, 2026. Deupirfenidone is an investigational therapy being advanced by PureTech's Founded Ent
- SECSEC Form 25 filed by PureTech Health plc25 - PureTech Health plc (0001782999) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PureTech Health plcSCHEDULE 13G/A - PureTech Health plc (0001782999) (Subject)
- INSIDERLarge owner Puretech Health Plc converted options into 16,382,534 shares (SEC Form 4)4 - PureTech Health plc (0001782999) (Reporting)
- INSIDERNew insider Puretech Health Plc claimed ownership of 302,479 shares (SEC Form 3)3 - PureTech Health plc (0001782999) (Reporting)
- SECSEC Form SCHEDULE 13G filed by PureTech Health plcSCHEDULE 13G - PureTech Health plc (0001782999) (Subject)
- SECSEC Form 20-F filed by PureTech Health plc20-F - PureTech Health plc (0001782999) (Filer)
- SECSEC Form 6-K filed by PureTech Health plc6-K - PureTech Health plc (0001782999) (Filer)
- SECSEC Form 6-K filed by PureTech Health plc6-K - PureTech Health plc (0001782999) (Filer)
- PRPureTech Announces Annual Results for Year Ended December 31, 2025Refined strategy and disciplined execution position Company to unlock value from its portfolio, which includes Celea Therapeutics' Phase 3-ready deupirfenidone for idiopathic pulmonary fibrosis, Gallop Oncology's clinically-validated LYT-200 for myeloid malignancies, and Seaport Therapeutics' advancing clinical-stage pipeline for neuropsychiatric disorders PureTech level cash, cash equivalents and short-term investments of $277.1 million1 and Consolidated cash, cash equivalents and short-term investments of $277.3 million1 as of December 31, 2025; Operational runway at least through the end of 2028, inclusive of the Company's expected participation in Founded Entity fundraisings As of M
- PRPureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock ExchangePureTech to maintain its primary listing on the London Stock Exchange Simplification of listing structure expected to enhance operational efficiency and focus resources on advancing the Company's portfolio PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that it has notified The Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its American Depositary Shares ("ADSs"), each representing the right to receive ten (10) ordinary shares of the Company. Following the effectiveness of the delisting, PureTech's ord
- PRPureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of DirectorsPureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the appointment of Dr. Sharon Mates to its Board of Directors. Dr. Mates served as the Co-Founder, Chairman, and Chief Executive Officer of Intra-Cellular Therapies, Inc. from inception of the company in June 2002 until its acquisition by Johnson & Johnson (J&J) in 2025 for approximately $14.6 billion. She has decades of experience in neuropsychiatry, guiding a company she founded through successful commercialization and a major st
- PRPureTech Health: Notice of ResultsPureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2025, on Wednesday, April 29, 2026. A presentation and conference call to discuss the results will take place at 9:00 AM EDT / 2:00 PM BST on the day of publication, and a webcast of the presentation will be available on the Company's website at https://investors.puretechhealth.com/events-presentations. About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D mo
- PRPureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care MedicineDeupirfenidone 825 mg TID monotherapy significantly slowed lung function decline versus placebo at 26 weeks in people with idiopathic pulmonary fibrosis (adjusted mean FVC difference 91 mL; p=0.02), approaching the lung function change expected in normal, healthy aging First industry-sponsored IPF trial to include a current standard-of-care treatment as an active comparator in addition to a placebo arm, strengthening interpretation of efficacy and safety findings PureTech's Founded Entity, Celea Therapeutics, is working to complete a financing to enable the initiation of the Phase 3 SURPASS-IPF trial in the first half of 2026 PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" o
- PRPureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy VolunteersPureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced positive topline data from portions of its ongoing Phase 1 proof-of-concept clinical trial evaluating GlyphAgoTM (SPT-320TM or Glyph Agomelatine). GlyphAgo is a novel, Glyphed oral prodrug of agomelatine in development for generalized anxiety disorder (GAD) and the second clinical-stage candidate from Seaport's pipeline. Based on the data shared today, Seaport announced plans to advance GlyphAgo into two parallel trials, a Phase 2a
- PRPureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in HumansPureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, today announced the publication of first-in-human clinical and preclinical data for GlyphAllo™ (SPT-300 or Glyph Allopregnanolone) in Science Translational Medicine. The GlyphAllo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company's strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now bei
- PRPureTech to Present at the Leerink Partners Global Healthcare ConferencePureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that Robert Lyne, Chief Executive Officer, and Eric Elenko, PhD, Co-founder and President, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026, at 11:20am EDT. A webcast of the presentation will be available at https://investors.puretechhealth.com. About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this thr
- PRPureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary FibrosisDesignations provide market exclusivity as well as other development incentives PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that the U.S. Food and Drug Administration (FDA) and European Commission have granted Orphan Drug Designation to deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and fatal lung disease. Deupirfenidone is being advanced by Celea Therapeutics, a Founded Entity established by PureTech to lead its late-stage development and potential commercialization.
- PRPureTech to Present at 44th Annual J.P. Morgan Healthcare ConferencePureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced that Robert Lyne, Chief Executive Officer, will present at the 44th annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 4:30pm PST / 7:30pm EST. A webcast of the presentation will be available at https://investors.puretechhealth.com. About PureTech Health PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opp
- SECSEC Form 6-K filed by PureTech Health plc6-K - PureTech Health plc (0001782999) (Filer)
- PRPureTech Appoints Robert Lyne as Chief Executive OfficerPureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251217152848/en/Robert Lyne, Chief Executive Officer of PureTech Robert Lyne commented: "I'm honored to lead PureTech as CEO at such an important moment in its evolution. Over the past two years, I've seen first-hand the streng
- SECSEC Form 6-K filed by PureTech Health plc6-K - PureTech Health plc (0001782999) (Filer)
PRTC FAQ
6 questionsWhat does PureTech Health plc do?
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical...Where does PRTC stock trade?
PureTech Health plc (PRTC) is listed on NASDAQ.What sector and industry is PRTC in?
PureTech Health plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PRTC?
PureTech Health plc has had 3 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform with a $4500.00 price target on 2024-09-09. Recent price targets cluster around $4500.00.What companies are similar to PRTC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare PRTC side-by-side with any of them on Quantisnow.How can I track PRTC on Quantisnow?
Quantisnow aggregates PureTech Health plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRTC to receive live email and push alerts on every new disclosure.